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Abstract: With the dissemination of optical coherence tomography over the past two decades, 
the role of persistent vitreomacular adhesion (VMA) in the development of numerous macular 
pathologies – including idiopathic macular hole, vitreomacular traction syndrome, cystoid and 
diabetic macular edema, neovascularization in diabetic retinopathy and retinal vein occlusion, 
exudative age-related macular degeneration, and myopic traction maculopathy – has been estab-
lished. While invasive vitreoretinal procedures have long been utilized to address complications 
related to these disorders, such an approach is hampered by incomplete vitreoretinal separation 
and vitreous removal, surgical complications, and high costs. In light of such limitations, inves-
tigators have increasingly looked to nonsurgical means for the treatment of persistent pathologic 
VMA. Chief among these alternative measures is the intravitreal application of pharmacologic 
agents for the induction of vitreous liquefaction and/or vitreoretinal separation, an approach 
termed pharmacologic vitreolysis. This article aims to review the available evidence regarding 
the use of pharmacologic agents in the treatment of VMA-related   pathology. In addition, a 
discussion of vitreous molecular organization and principles of physiologic posterior vitreous 
detachment is provided to allow for a consideration of vitreolytic agent mode of action and 
molecular targets.
Keywords: macular edema, macular hole, microplasmin, pharmacologic vitreolysis, posterior 
vitreous detachment, vitreomacular traction syndrome
Introduction
Perhaps owing to its fundamentally “invisible” nature, the vitreous has long been an 
under recognized cause of macular pathology. More recently, the improved charac-
terization of vitreomacular relationships facilitated by the evolution of optical coher-
ence tomography (OCT) has led to an increasing recognition of the role played by the 
posterior vitreous in such disorders. Numerous investigators have found an increased 
prevalence of incomplete posterior vitreous detachment – a surrogate marker for persis-
tent vitreomacular adhesion (VMA) – in association with a number of retinal disorders 
including idiopathic macular hole,1 vitreomacular traction syndrome (VMT),2 cystoid 
(CME)3 and diabetic macular edema (DME),4 neovascularization in diabetic retinopa-
thy5 and retinal vein occlusion (RVO),6 exudative age-related macular degeneration 
(ARMD),7 and myopic traction maculopathy.8 The pathologic role of VMA in many 
of these disorders relates to the transmission of static and dynamic anteroposterior 
tractional forces to the macular surface. The specific pathologic phenotype produced 
depends on the size and strength of the adhesion, with more extensive vitreous separa-
tions and smaller areas of vitreous adhesion imparting greater tractional force.8,9 The Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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role of vitreoretinal and/or vitreomacular adhesion (h  ereafter 
referred to collectively as VMA) in the development of 
n  eovascularization and nontractional macular edema is 
less well defined. It may be due in part to residual posterior 
cortical vitreous acting as a barrier to the flux of important 
intravitreal molecules10 (specifically oxygen, growth factors, 
and cytokines) or as a scaffold for the growth of fibrovascular 
proliferation arising from the retinal surface.11
Of note, careful distinction should be made between 
pathologic (or “symptomatic”) VMA, a categorization that 
encompasses the pathologic entities described above, and 
nonpathologic (or “asymptomatic”) VMA in which persistent 
attachment of the posterior vitreous to the macula does not 
result in anatomic or functional impairment. This latter form 
of VMA is frequently noted incidentally on OCT imaging and 
represents a physiologic stage I posterior vitreous detachment 
(PVD).8,9 Taken in sum, these descriptions can be utilized to 
generate a mechanistic classification of disorders associated 
with pathologic VMA, detailed in Figure 1.
With the introduction of pars plana vitrectomy by 
Machemer et al in 1971,12 a definitive solution for VMA-
related disease became available to vitreoretinal surgeons. 
While implementation lagged in line with the delay in rec-
ognizing the etiologic role played by the posterior vitreous, 
the past two decades have seen a dramatic upswing in the 
application of vitrectomy. In many cases, elimination of 
vitreoretinal traction and complete separation of the posterior 
hyaloid from the retinal surface with removal of all vitre-
ous gel lead to both anatomic and functional   improvement. 
Though outcomes have improved with advancements in 
instrumentation and technique, the utility of vitrectomy 
remains limited by incomplete vitreoretinal separation and 
vitreous removal, associated complications, and high costs. 
Clinical and histologic studies have shown that residual corti-
cal vitreous commonly adheres to the inner retinal s  urface 
following vitrectomy despite concentrated as  piration and 
peeling of the posterior hyaloid.13–15 Cortical vitreous rem-
nants may organize into a fibrocellular epiretinal membrane 
with subsequent contraction causing macular pucker.16 
Indeed, patients with pathologic VMA inherently have exag-
gerated adherence at the vitreoretinal interface, which in turn 
leads to a more difficult mechanical separation. Attempts to 
achieve a cleaner cleavage plane, through mechanical peel-
ing of the internal limiting membrane (ILM), may increase 
the risk of surgical complications, including retinal hemor-
rhages, retinal breaks, nerve fiber layer (NFL) damage, and 
paracentral scotomas.17–19
In light of the inherent limitations associated with vitrec-
tomy for the treatment of pathologic VMA, it is unsurprising 
that, over the past 15 years, investigators have increasingly 
examined alternative methods for induction of PVD. Though 
a few investigators have explored mechanical PVD induction 
with isolated intraocular gas injection20–22 and even LASIK 
(laser-assisted in-situ keratomileusis) suction rings,23,24 the 
bulk of efforts have focused on the use of pharmacologic 
agents to modify the molecular structure of the vitreous in 
order to eliminate its role in disease, a technique termed 
pharmacologic vitreolysis.25 In general, this involves the 
induction of vitreoretinal separation and/or liquefaction of 
vitreous gel either as monotherapy or in conjunction with 
vitrectomy. This article aims to review the available evidence 
to date regarding the application of pharmacologic agents in 
the endeavor of vitreolysis. A summary of vitreous molecular 
organization and principles of physiologic PVD will provide 
context for the consideration of vitreolytic agent mode of 
action and molecular targets. Following a careful analysis 
of specific indications for pharmacologic vitreolysis, the 
individual agents will be reviewed with summaries to include 
postulated mechanism of action, results of past pre-clinical 
and clinical trials (if available) as well as a discussion of any 
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pending investigations. A final section on emerging trends 
and future directions will conclude the review.
Vitreous molecular organization 
and structure
Pharmacologic vitreolysis is largely an outgrowth of an 
evolving understanding of the molecular organization, 
structure, and physiology of the vitreous. This knowledge 
has allowed for the selection of appropriate agents to target 
key molecules and structures within the vitreous gel as well 
as at the vitreoretinal interface.
Consistent with its dual purpose of maintaining media 
clarity and mitigating possible concussive effects associated 
with ocular movement or trauma,26 the vitreous is a transpar-
ent viscoelastic extracellular gel matrix (ECM) composed of 
approximately 99% water.27 In the gel state, vitreous further 
maintains media clarity by acting as a barrier to limit cellular 
invasion27 and may also act to protect sensitive tissues such as 
the crystalline lens and trabecular meshwork from oxidative 
damage via its role in oxygen metabolism.28,29 These unique 
properties are a direct result of the molecular structure of 
vitreous gel, which consists of two complementary macromo-
lecular structures: a fibrillar component, represented by col-
lagen; and glycosaminoglycans (GAGs), chiefly hyaluronan 
with a lesser concentration of chondroitin sulfate. Vitreous 
collagen consists of heterotypic fibrils composed of a com-
bination of collagen type II, type IX, and a hybrid type V/XI. 
The core of each fibril is composed of type V/XI collagen, 
which is surrounded by a sheath of fibrillar type II collagen 
as well as a regular arrangement of type IX collagen along 
the outermost surface of the fibril.27 The rope-like structures 
formed are largely resistant to proteolysis except by a few 
select proteases – bacterial collagenase, cathespin K, and 
certain matrix metalloproteinases.30 The heterotypic fibrils 
are arranged into interconnecting bundles that form an 
extended network, which provides shape, strength, and flex-
ibility to the vitreous and allows it to resist tractional forces. 
As mentioned above, the GAG component is predominantly 
hyaluronan (.90%) along with chondroitin sulfate, which 
is found only in proteoglycan form (attached to a protein 
core) as either versican or collagen type IX.27 The negatively 
charged disaccharide moieties of hyaluronan attract a shell 
of water molecules that act to inflate the collagen matrix 
and provide swelling pressure to resist compressive forces. 
  Chondroitin sulfate appears to be involved in the maintenance 
of interfibrillar spacing via interconnections between collagen 
fibrils mediated through links to opticin, a small leucine-rich 
repeat protein.31
As the site of adhesion between the posterior cortical 
  vitreous and the ILM, the vitreoretinal interface plays a 
decisive role in the relationship between physiologic and 
pathologic VMA. The interface juxtaposes the ILM, a base-
ment membrane secreted by underlying Müller cells, and 
the posterior hyaloid. Similar to basal membranes elsewhere 
in the body, the ILM is compromised chiefly of collagen 
type IV ,32 which imparts a sheet-like conformation, in addition 
to several ECM proteins, notably laminin, fibronectin,33 and 
collagen type XVIII.34 Despite this expanding knowledge of 
vitreoretinal interface components, the mechanisms underly-
ing VMA remain poorly understood. Histologic studies have 
demonstrated that vitreous collagen fibrils are oriented in an 
anteroposterior manner and, posterior to the vitreous base, run 
parallel to the ILM.35 However, at the vitreous base, vitreous 
collagen fibrils run perpendicular to and pass through the ILM 
where they insert to form an adhesion, considered unbreak-
able without proteolysis.36,37 This contrasts with the posterior 
vitreoretinal interface at which collagen fibrils do not insert 
into the ILM. Instead, VMA posterior to the vitreous base is 
thought to be fascial in nature and mediated by some form 
of “extracellular matrix glue” that connects cortical vitre-
ous collagen fibrils with the ILM surface.38 ILM-associated 
molecules suggested as potential “glue” components include 
laminin and fibronectin, which have been demonstrated to 
have high affinity for collagen,39,40 as well as collagen type 
XVIII, which has been shown to be bound by the opticin 
molecules coating vitreous collagen fibrils.31
Principles of physiologic PVD
The process of physiologic, or age-related, PVD is well char-
acterized from a mechanistic standpoint, but remains poorly 
understood on a molecular level. While the lack of an accu-
rate molecular description has hampered the development of 
pharmacologic vitreolytics, improved understanding of the 
physical sequence of uncomplicated PVD has shed significant 
light on ways in which it may go awry and induce pathologic 
sequelae. Within the vitreous gel, two related processes, liq-
uefaction (synchysis) and fibrillar collapse (syneresis), act as 
the primary motive force driving vitreoretinal separation.41,42 
Liquefaction originates in the premacular cortical vitreous 
where it has been detected as early as 2 years of age in fixed 
autopsy specimens.43 Focal collections of liquefaction, or 
liquefied lacunae, subsequently form throughout the vitre-
ous, increasing in number and size during adolescence and 
adulthood.41–44 This process culminates in the coalescence 
of extensive areas of synchysis, with approximately 70% of 
autopsy eyes obtained from donors aged 70 years and greater Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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demonstrating at least 50% liquefaction of the   vitreous body.41 
As liquefaction progresses, the collagen fibrillar meshwork 
undergoes collapse. This leads to the aggregation of collagen 
into parallel bundles that form thick fibers, seen clinically 
as syneretic debris, which become progressively dense and 
tortuous with age.35,44 In line with the demonstrated positive 
correlation between the extent of synchysis/syneresis and 
PVD incidence,41,45,46 liquefaction with subsequent collapse 
appears to drive vitreoretinal separation following attenua-
tion of the adhesion between the cortical vitreous and ILM 
of the posterior pole. Though previous investigators believed 
it to be an acute process,41,47 more recent studies indicate that 
PVD occurs over months to years, beginning as a shallow 
perifoveal vitreoretinal separation that expands gradually 
until complete PVD is achieved with acute separation of the 
vitreous from the optic disc margin.8,9
The weakening of the adhesion between the vitreous and 
the retina stands as a critical factor in the timing and progres-
sion of PVD. Multiple studies have demonstrated that the 
majority of patients less than age 60 have an intact vitreoreti-
nal interface despite the presence of extensive liquefaction.41,45 
After age 60, however, there is a much stronger correlation 
between PVD incidence and extent of liquefaction, indicating 
the presence of some factor that enhances the effect of lique-
faction and collapse on PVD induction; this factor is likely a 
weakened adhesive force between the retina and vitreous.41,45 
Variations in strength of this force likely determine whether 
a given PVD is accompanied by pathologic sequelae. In a 
subset of eyes, age-related PVD progresses normally except 
where especially firm vitreorentinal adhesions are encoun-
tered in the macula, at the optic disc margin, or at focal sites 
in the retinal periphery. In such eyes, dynamic (saccadic) 
vitreous traction is exerted upon the retina at the residual 
adhesion site(s), leading to various complications including 
macular hole, VMT, tractional DME, vitreopapillary traction 
syndrome (VPT), vitreous hemorrhage, and retinal tears.8,9 
Sebag coined the term “anomalous PVD,” to describe the 
condition in which the extent of gel liquefaction and collapse 
exceed the attenuation of vitreorentinal adhesion.48 This con-
dition results from disorders that cause premature vitreous 
liquefaction, including hereditary vitreoretinal syndromes, 
uveitis, vitreous hemorrhage, and high myopia, and increases 
the risk of PVD-associated morbidity.
To improve upon existing mechanical methods for the 
treatment of pathologic PVD, controlled induction of vitre-
ous liquefaction and weakening of vitreorentinal adhesion 
will be necessary.   Targeted pharmacologic agents, capable 
of altering the molecular organization of the vitreous gel and 
vitreoretinal interface, have the potential to provide such 
control.25 Unfortunately, the development of these agents has 
been slowed by the lack of accurate molecular descriptions of 
the processes in   question. As mentioned above, the basis of 
vitreorentinal adhesion remains poorly described. The same is 
true of the physiologic weakening of vitreorentinal adhesion 
that accompanies aging. Investigators have proposed several 
possible age-related changes – including alterations in Mül-
ler cell function,49 thickening of the ILM,50 or the cumulative 
effects of incident light-generated free radicals51 – as a basis 
for this weakening. Similarly, models of age-related vitre-
ous liquefaction, implicating incident light-generated free 
radicals52–54 or enzymatic degradation of collagen,55–57 have 
been suggested but remain largely unproven.
Indications for pharmacologic 
vitreolysis
From a pathophysiologic perspective, any manifestation 
of pathologic VMA should benefit from pharmacologic 
vitreoretinal separation, based on either release of anteropos-
terior traction (tractional VMA) or removal of premacular 
vitreous cortex (nontractional VMA). While this may be 
true in principle, the selection of appropriate indications for 
pharmacologic vitreolysis requires careful consideration of 
utilization models and therapeutic goals.
While early interest in pharmacologic vitreolysis focused 
on its application as an adjunct to vitrectomy and removal 
of fibrovascular proliferative membranes,58–60 investigators 
quickly realized its potential as a stand-alone therapy.61–63 
Indeed, clinical applications of pharmacologic vitreolysis can 
be broadly grouped into two categories based on utilization 
model: pharmacology-assisted vitrectomy and pharmacologic 
PVD induction. In the former model, a pharmacologic agent 
administered preoperatively acts to either induce vitreous 
liquefaction, allowing for more rapid vitreous removal, or 
weaken the vitreorentinal adhesion, allowing for greater ease 
of mechanical PVD induction with a cleaner vitreoretinal 
separation.15,64–67 More rapid vitreous removal translates 
into shorter surgical times15,25,68 and possibly an increased 
ability to employ smaller gauge instrumentation,69,70 which 
are associated with reduced postoperative recovery times.71,72 
Weakening of the vitreorentinal adhesion allows mechanical 
PVD creation without the use of high suction, which reduces 
the risk of iatrogenic tears73,74 and permits the use of smaller 
gauge instrumentation not capable of achieving such high 
levels of aspiration.69,75,76 Theoretically, it also facilitates 
cleaner vitreoretinal separation, avoiding cortical vitreous 
remnants and thereby reducing postoperative complications Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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such as macular pucker,77 proliferative vitreoretinopathy 
(PVR),78,79 and persistence of diabetic retinopathy-related 
complications.80
When pharmacologic vitreolysis is used as stand-alone 
therapy, vitreolytic agents can be employed either as a 
definitive treatment in active VMA-related disease or as a 
prophylactic measure in conditions in which PVD is associ-
ated with an improved prognosis. Examples of the former 
include early macular holes, VMT, VPT, and tractional DME/
CME,8,9,48 while the latter includes conditions such as DME,4 
proliferative diabetic retinopathy (PDR),5,81,82 RVO, 6,83–85 and 
ARMD.7,86,87 In all cases, the therapeutic effect results from 
induction of complete pharmacologic PVD. The basis of the 
prophylactic benefit of PVD in macular edema and neovas-
cularization remains unclear, but likely relates to the barrier 
and scaffold functions played by posterior cortical vitreous 
discussed earlier. Of note, stand-alone vitreolytic therapy 
has also been utilized strictly for its liquefactive properties 
in conditions such as non-clearing vitreous hemorrhage;88,89 
however, this indication is outside the scope of this review 
as it does not pertain to VMA-related disease.
As is the case with most ophthalmologic therapeutic 
interventions, pharmacologic vitreolysis is indicated in the 
conditions discussed above based on its potential to improve 
anatomical and functional outcomes. In addition to this 
primary therapeutic objective, ancillary goals should also 
be considered, including: decreased costs, based on shorter 
surgical times or decreased incidence of progressive disease 
requiring surgery; and greater access to therapy, based on 
the simple instrumentation involved and a possible transi-
tion to office-based procedures.25,68,90 A reduction in surgi-
cal cases, due to either a decreased incidence of advanced 
disease following prophylactic therapy or due to a transition 
to office-based treatment of VMA-related disease, would 
have the additional benefit of reducing patient exposure to 
vitrectomy-related complications – such as endophthalmitis, 
cataract, and iatrogenic breaks – as well as complications 
related to anesthesia.
Vitreolytic agents
Overview
The biochemical properties requisite in any potential 
vitreolytic agent include the ability to induce vitreous liq-
uefaction (liquefactants), weakening of the vitreorentinal 
adhesion (interfactants), or both.25,90 These molecular altera-
tions may be accomplished through either nonenzymatic, 
or more commonly, enzymatic means. Based on these 
characteristics, the available vitreolytic agents – including 
those previously tested as well as those that remain under 
development – can be classified as detailed in Table 1.25,90 
The following section aims to review the mechanism of 
action of each agent and summarize the results of relevant 
pre-clinical and clinical trials.
Collagenase
Bacterial collagenase, purified from Clostridium histolyticum, 
is one of the few proteases known to cleave the type II 
collagen comprising the fibrillar network of the vitreous gel.30 
In contrast to fibrillar collagen, the resulting proteolyzed 
fragments are soluble, allowing for spontaneous denatur-
ation and further degradation by nonspecific proteases.91 
Prolonged intravitreal incubation of escalating doses of 
bacterial collagenase in rabbits resulted in dose-dependent 
liquefaction, but was accompanied by ILM damage and dis-
ruption of retinal architecture at doses achieving clinically 
significant degrees of liquefaction.92 Using lower doses and 
shorter incubation periods, subsequent studies in a rabbit 
model of PVR demonstrated some focal fibrovascular mem-
brane digestion prior to vitrectomy, although histologic and 
electrophysiologic toxicity was noted at incubation periods 
greater than 30 minutes.58,60 Later human pilot studies of 
collagenase-assisted vitrectomy resulted in hemorrhages on 
the surface of the retina as well as evidence of digestion of 
retinal vasculature on proliferative membranes,59,81 which 
confirmed earlier reports of severe retinal hemorrhages in 
rabbits.93
Chondroitinase
Although substrate specificity varies depending on the bac-
terial species of origin, chondroitinase catalyzes the depo-
lymerization of various GAGs including chondroitin sulfate, 
hyaluronan, and dermatan sulfate.94 The role of chondroitin 
sulfate within the vitreous remains unclear. It is generally 
found in proteoglycan form as either versican, which is linked 
to hyaluronan, or as collagen IX, which coats the heterotypic 
Table1 Classification of pharmacologic vitreolytic agents
Interfactants Liquefactants Combination
enzymatic Dispase Hyaluronidase  
Collagenase
Plasmin 
Microplasmin 
tPA ± 
plasminogen 
Nattokinase 
Chondroitinase
Nonenzymatic RGD peptides vitreosolvea
Note: avitreosolve® (vitreoretinal Technologies inc, irvine, CA).
Abbreviations: RGD, arginine-glycine-aspartate; tPA, tissue plasminogen activator.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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vitreous collagen fibrils.27 Some investigators believe it may 
contribute to vitreous structure or spacing by linking the 
hyaluronan network to other integral ECM components,27 
while others have reported it may play a role in vitreorentinal 
adhesion based on immunolocalization of chondroitin sulfate 
to the vitreous base and papillary margin.95 Early pre-clinical 
results examining the vitreolytic potential of chondroitinase 
were mixed. One group found intravitreal chondroitinase 
to have no effect on vitreous liquefaction or vitreorentinal 
adhesion in a rabbit model,93 while a second group found 
complete vitreous body disinsertion, including at the vitreous 
base, prior to vitrectomy in cynomologus monkeys as well 
as in a limited number of human cadaver eyes.95 This latter 
group also found no microscopic, immunohistochemical, 
or electroretinography (ERG) evidence of retinal toxicity 
up to 16 months f  ollowing the procedure.95 Two studies 
comparing the liquefactive capacity of chondroitinase to 
hyaluronidase and plasmin in animal models demonstrated 
modest reduction in wet weight following 48-hour incuba-
tion of isolated vitreous gel as well as a mild enhancement 
of gel removal during standardized vitrectomy following 1 
and 3 hours incubation.96,97 The significantly lower doses used 
in these studies did not appear to induce an accompanying 
gel collapse,96 but were associated with mild ILM or NFL 
damage in the vitrectomy-based study.97 In a later study 
evaluating PVD induction in an enzyme-assisted vitrectomy 
model in pigs, chondroitinase, at similarly low doses, failed to 
achieve a significant improvement in the rate of spontaneous 
PVD, the extent of PVD, or the degree of residual collagen 
detected on electron microscopy (EM) when compared with 
controls.98 Thus, initial encouraging results were unable to 
be duplicated in later trials using much lower doses, which 
did still demonstrate some limited toxicity.
Hyaluronidase
Hyaluronidase is an endoglycosidase capable of cleaving 
bulky hyaluronan molecules, in addition to other GAGs 
such as chondroitin sulfate, into much smaller fragments.99 
The resulting decreased viscosity within the ECM allows for 
easier passage of material through the ECM. This property 
has already been exploited clinically to increase the absorp-
tion and dispersion of injected drugs such as anesthetics.100 
As hyaluronan plays a critical role in maintaining the 
gel-like character of the vitreous, hyaluronidase possesses 
considerable potential as a liquefactive agent. Hyaluroni-
dase-mediated vitreous liquefaction has been demonstrated 
both in vitro96 and in vivo,101,102 and more recently, in Phase 
III trials studying its potential in speeding the clearance 
of vitreous hemorrhage.88,89 Additionally, hyaluronidase 
was shown to significantly improve the extent of vitreous 
removal during standardized vitrectomy compared with 
untreated eyes after incubations of 1 or 3 hours.97 In view of 
the clear association between age-related PVD and vitreous 
liquefaction, hyaluronidase would seem a logical agent for 
pharmacologic induction of PVD. Initial studies examining 
low dose (1 U) intravitreal hyaluronidase in conjunction with 
perfluoropropane gas in a rabbit model exhibited only partial 
PVD following 3-day incubations; this contrasted with eyes 
receiving either hyaluronidase or gas alone, in which no PVD 
was detected.103 Using higher doses (5–20 U) of hyaluroni-
dase alone in a similar rabbit model, two follow-up studies 
produced very different outcomes: one reported gradual 
development of PVD at 5–8 weeks in nearly all experimental 
eyes at the highest doses (10 and 20 U),62 while a later study 
reported no PVD in any experimental eye at 3 and 6 months 
using a similarly high dose (20 U).104 Although the source 
of the discrepancy is unclear, the authors of the latter study 
implicated inadequacy of the light microscopy and clinical 
examination for PVD determination employed in the former 
study compared with the EM techniques utilized in their 
own study.104 The poor performance of hyaluronidase (20 
U) in PVD induction was confirmed by a separate group, 
again using EM to assess PVD status, though the incubation 
period in this study was considerably shorter at 1 week.105 In 
terms of safety, hyaluronidase was generally well tolerated 
up to doses of 20 U at incubation periods ranging from 3 to 
28 days.62,102,103,105 Aside from transient vitreous haze noted 
at nearly all doses and incubation periods,62,102–105 there 
was no evidence of retinal structural toxicity, as assessed 
by EM,102,103,105 nor functional toxicity, as assessed by 
ERG.62,103,105 Reported toxicities at higher doses were mixed, 
with one group demonstrating disruption of retinal cellular 
anatomy at doses as low as 30 U (bovine hyaluronidase) 
for 1 week, while the large Phase III trial using doses of 55 
and 75 IU (ovine hyaluronidase) reported only an increased 
rate of transient moderate-severe iritis.89 Despite impressive 
liquefactive capacity, hyaluronidase appears limited in terms 
of PVD induction as it has no demonstrated impact on the 
vitreoretinal interface. Investigators hypothesized that the 
induction of PVD by hyaluronidase follows liquefaction of 
central vitreous, with collapse and subsequent loss of sup-
port for cortical vitreous fibers, rendering it susceptible to 
separation by mechanical forces such as eye movements.62,104 
In effect, hyaluronidase produces PVD through an increase in 
vitreoretinal traction and may worsen existing VMA-related 
pathologies.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Dispase
A neutral protease obtained from Bacillus polymyxa, dispase is 
known to cleave type IV collagen and fibronectin while laminin 
and other collagen subtypes are left largely unaltered.106 Given 
its activity against type IV collagen, a major component of the 
ILM, and fibronectin, postulated to be a factor in vitreorentinal 
adhesion, dispase was tabbed as a vitreolytic agent based on 
its potential to mediate vitreoretinal   disinsertion. Interest-
ingly, dispase was initially utilized intravitreally to generate 
an animal model of PVR without the addition of exogenous 
cells.107,108 This model was based on the ability of dispase to 
release endogenous cells – such as fibroblasts, macrophages, 
and glial cells – from their cellular attachments and recruit 
them into the vitreous. As PVR generation was achieved with 
prolonged incubations at very low doses (0.01–0.50 U),107,108 
later studies investigating the utility of dispase in PVD induc-
tion used shorter incubation periods (15–120 minutes) at the 
same or higher doses.63,109–111 In effect, dispase was only evalu-
ated as an agent for enzyme-assisted vitrectomy due to the fact 
that removal of the enzyme following a specified incubation 
would be required to avoid PVR development. In the two 
earliest such studies, dispase achieved significantly higher 
rates of spontaneous complete PVD in enucleated pig and 
human eyes as well as pig eyes in vivo at the majority of doses 
tested following 15 or 120 minutes of incubation.63,109 Neither 
study revealed significant toxicity, excepting transient vitreous 
haze.63,109 In contrast, a similar study of dispase-assisted vit-
rectomy in rabbits in vivo using greater doses and incubation 
times failed to show any effect on PVD induction, and enzyme 
use was associated with retinal and vitreous hemorrhages.110 
Further evidence of dispase-associated toxicity was found in 
two follow-up studies in an in-vivo rabbit model: in addition 
to vitreous hemorrhage and cataract formation, histologic 
exam revealed disruption of ganglion cell and photorecep-
tor layers, while ERG testing revealed significant depression 
of a- and b-wave amplitudes.111,112 These studies did employ 
longer incubations (1 week), but clinical evidence of toxicity 
was noted as early as 30 minutes following injection.111,112 
The reason for the conflicting results regarding the safety and 
efficacy of dispase in vitreolysis is unclear but may be related 
to the model used. Regardless, given its ability to generate 
PVR as well as its action on collagen IV , a major component 
of the ILM and lenticular capsule, the safety of dispase remains 
questionable at best.
Nattokinase
Originally discovered in the Japanese soybean cheese 
natt , nattokinase is a serine protease produced by Bacillus 
subtilius.113 Although incompletely characterized, it is 
known to possess potent fibrinolytic effects likely due to its 
e  nhancement of plasmin activation via increased synthesis of 
tissue plasminogen activator (tPA)114 as well as inactivation of 
plasmin activator inhibitors.115 Additionally, nattokinase has 
direct proteolytic effects on collagen.116 Thus, the postulated 
PVD induction mechanism of nattokinase involves some 
combination of direct liquefaction and plasmin-mediated 
vitreoretinal dehiscence. In the rabbit model, intravitreal 
injection resulted in histologically confirmed PVD (eg, 
bare ILM) in all eyes at the two highest doses following 
30-minute incubations; however, eyes exposed to the highest 
dose displayed subtle alterations in inner retinal architecture, 
parapapillary retinal hemorrhages, and ERG depression.116 To 
date, no follow-up investigations have been conducted.
Plasmin
Undoubtedly the most widely studied vitreolytic agent, plas-
min is a serine protease with a critical role in   fibrinolysis. 
In addition to fibrin, plasmin has been shown to directly 
degrade other ECM components including laminin and 
fibronectin,117–119 which have a postulated role in vitreo-
rentinal adhesion.33 Plasmin may also indirectly generate 
increased levels of other nonspecific proteases such as matrix 
metalloproteinases120,121 and elastase,122 capable of cleaving 
further ECM structures. These downstream activities may 
enhance the primary action of plasmin – weakening of 
vitreoretinal insertion – or may allow for a limited degree 
of liquefaction. Initial studies of plasmin (1 U) with and 
without adjunctive vitrectomy61 or intraocular gas injection123 
in a rabbit model indicated that such adjunctive procedures 
were necessary to achieve clean vitreoretinal separation. 
Similar results were obtained in human cadaver eyes using 
a plasmin-assisted vitrectomy model in which the addition 
of 1 U of plasmin was found to eliminate the cortical vitre-
ous remnants noted on the ILM in untreated, vitrectomized 
eyes.15 Surprisingly, in follow-up studies by the same group 
in both enucleated pig124 and human eyes,119,125 short incuba-
tions (30–60   minutes) with similar doses of plasmin (1–3 
U) also resulted in a bare ILM without the use of adjunc-
tive techniques.   Further in-vivo studies in rabbits, however, 
indicated that the previous results in cadaver eyes may have 
been related to specific properties of post-mortem eyes, 
as very low rates of complete PVD were found following 
prolonged exposure (1 week) to 1 U of plasmin.105,112 Better 
rates of complete PVD were achieved with higher doses (4 
U).112 Several studies were able to demonstrate a correlation 
between both plasmin concentration and exposure time and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the resultant extent of vitreoretinal separation.61,119,124 The 
safety profile of intravitreal plasmin in these pre-clinical tri-
als was excellent. Excepting a consistent finding of transient 
vitreous haze,61,105,112,123 there were no reported toxicities 
despite thorough histologic examination with light and EM 
at doses up to 4 U and with exposure times ranging from 
30 minutes to 1 week.61,105,112,119,124,125 No functional toxicity 
was detected by ERG in three studies,105,112,123 while a fourth 
found only transient depression of b-wave amplitudes.61 
One group, using a plasmin-assisted vitrectomy model in 
enucleated pig eyes, reported rare ILM (0%–20%) and NFL 
(0%–10%) damage at doses of 3 and 30 U, with incubations 
of 1 and 3 hours.97
As plasmin is exceedingly unstable owing to rapid inac-
tivation via autolysis and binding to α2-antiplasmin, clinical 
application typically requires activation of its proenzyme, 
plasminogen, with plasminogen activators immediately prior 
to use. Application in human trials is further complicated by 
the lack of an approved, commercially available   plasminogen. 
In place of a commercial alternative, investigators have relied 
on the time-consuming and expensive process of autologous 
plasmin enzyme (APE) generation via harvesting a patient’s 
own plasma-derived plasminogen and purifying it via affinity 
  chromatography.126 Numerous human pilot studies used this 
technique to examine outcomes of plasmin-assisted vitrec-
tomy, with doses ranging from 0.03 U up to 2 U, in a variety 
of VMA-related   disorders. Because of the exceptionally 
strong vitreorentinal adhesion found in pediatric patients,50 
several groups examined the use of APE in the surgical 
treatment of pediatric traumatic macular holes,126,127 stage 5 
retinopathy of prematurity,128,129 and complicated X-linked 
retinoschisis;130 all reported improved anatomic outcomes 
compared with previously published studies. Other investi-
gators employed plasmin-assisted vitrectomy to treat full-
thickness macular holes in patients without pre-existing PVD 
and found high rates of spontaneous PVD intraoperatively, 
which reduced overall surgical time.131–133 The application of 
APE prior to vitrectomy resulted in nonsignificant increases 
in spontaneous PVD and ease of PVD induction in eyes 
with tractional DME77,134,135 and complicated PDR.136 One 
comparative study reported significantly higher visual acu-
ities at 1 year follow-up in patients with DME treated with 
APE compared with those not receiving such   treatment.134 
More recently, a small prospective study found that intra-
vitreal APE without vitrectomy improved central macular 
thickness and visual acuity in eyes with macular edema 
complicating branch RVO.137 Of note, many groups reported 
varying degrees of vitreous liquefaction following APE   
administration,77,127,131,133,135,136 although several others either 
did not comment or noted the lack of liquefaction.134 In this 
collection of pilot studies, no investigator reported a clear 
enzyme-related complication.
Plasminogen activators (tPA and urokinase 
[UK])
Potent fibrinolytic agents originally approved for a variety 
of nonophthalmologic vascular disorders including stroke, 
symptomatic coronary artery, and peripheral vascular 
occlusive disease, intraocular plasminogen activators have 
proven to be of modest utility in the treatment of several 
ophthalmologic conditions including post-surgical fibrin 
formation, submacular hemorrhage, and acute RVO.138,139 
As serine proteases capable of activating plasminogen, 
both tPA and UK exert their effects indirectly through 
plasmin. Several groups turned to plasminogen activators as 
potential vitreolytic agents in lieu of plasmin based on: (1) 
the ease of access to a US Food and Drug Administration-
approved commercially available formulation, (2) the 
safety of a recombinant molecule compared with blood 
derivatives in terms of microbial contamination, and (3) 
the established intraocular safety record based on its use 
for other indications.140 The challenge in working with 
plasminogen activators, however, lies in the need for 
clinically sufficient quantities of intraocular plasminogen, 
which outside the setting of pathologic blood–retinal barrier 
breakdown (ie, intraocular inflammation, hemorrhage, 
PDR),141 can typically only be achieved via iatrogenic blood–
retinal barrier breakdown (ie, cryopexy)142 or exogenous 
administration.143,144 In a rabbit model, cryopexy followed 
by tPA and limited vitrectomy (static core vitrectomy only) 
induced PVD in all treated eyes, whereas no PVD was noted 
in eyes not receiving either cryopexy or tPA injection.142 
Two later in-vivo rabbit studies examined the efficacy of 
UK plus exogenous plasminogen with differing results.143,144 
Complete PVD was noted in all eyes at the two highest 
nontoxic doses of UK plus purified human plasminogen,143 
but only occurred with the addition of intraocular sulfur 
hexafluoride following UK plus recombinant plasminogen 
in a later study.144 In human pilot studies, tPA-assisted 
vitrectomy in patients with complicated PDR was not 
associated with spontaneous PVD induction (assessed 
intraoperatively) nor with any significant improvement in 
postoperative functional outcomes.145 However, a subsequent 
report of tPA injection alone in patients with RVO-associated 
macular edema revealed post-treatment PVD in a majority 
of patients that correlated with improved functional and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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anatomic outcomes.146 Overall, plasminogen activators, 
much like plasmin, have a promising efficacy and safety 
record, but their therapeutic potential will continue to be 
limited by the need for adequate concentrations of intraocu-
lar plasminogen substrate. Assuring sufficient quantities 
of plasminogen, either through exogenous administration 
or blood–retinal barrier breakdown, inevitably leads to 
imprecise dosing.
Microplasmin
Another agent initially developed for systemic admin-
istration in the treatment of cerebral thromboembolic 
disease, microplasmin is a recombinant molecule, highly 
expressed in the Pischia pastoris yeast expression sys-
tem, consisting solely of the catalytic domain of human 
plasmin.147 It has several advantages over plasmin: (1) it 
is commercially available, allowing investigators to avoid 
the time-intensive and expensive production of APE; 
(2) it is generated by recombinant techniques, assuring its 
sterility and avoiding the risk of microbial contamination; 
(3) it is much smaller than plasmin (22 versus 88 kDa), 
which theoretically would allow for greater penetration of 
epiretinal tissues; and (4) it is inherently more stable than 
plasmin and can be stored in citrate buffer prior to use.147–149 
It is thus unsurprising – given the greater safety, ease of 
administration, and dosing accuracy – that investigators 
increasingly turned to microplasmin for the treatment of 
VMA-related pathologies in favor of either plasmin or 
plasminogen activators. The initial pre-clinical studies 
revealed achievement of complete PVD (eg, bare ILM) at 
doses ranging from 62.5–125.0 µg (equivalent to 1–2 U of 
plasmin) in enucleated human eyes with or without adjunc-
tive intraocular gas.148 In-vivo studies similarly exhibited 
complete PVD following 7–21 day intravitreal microplas-
min exposure with doses differing based on species; cat 
eyes achieved PVD at doses of 14.5–25.0 µg,148 while 
two separate studies in rabbits reported consistent PVD at 
doses of 125–250 µg.149,150 No histologic toxicity148–150 or 
functional toxicity149 was noted excepting persistent a- and 
b-wave depression on ERG testing in the 250 µg group 
only. A later study in enucleated pig eyes utilized a dose- 
(range 62.5–400 µg incubated for 1 or 2 hours) and expo-
sure time-escalation (range 15–120 minutes after 125 µg 
administration) design.151 Their results demonstrated 
both time- and dose-dependent PVD development with a 
minimal effective dose of 125 µg and a minimal effective 
incubation period of 60 minutes with 125 µg dose. These 
values may have been somewhat inflated by the use of room 
temperature incubations. Although no disruption of cellular 
anatomy was noted in any experimental eye, serous-like 
retinal elevations were detected in 25% of eyes exposed to 
400 µg for 120 minutes and scattered dendritic-like cells 
were found on the ILM in eyes receiving doses of 125 µg 
or higher for 120 minutes, with a greater number of cells 
in eyes administered higher doses.
Based on the promising anatomic and safety profile 
reported in these pre-clinical studies, a series of clinical 
trials was undertaken collectively entitled the Microplas-
min Intravitreal Injections (MIVI) trials. MIVI-I was an 
uncontrolled Phase I/IIa clinical trial designed to assess 
safety and preliminary efficacy at various doses (25, 50, 75, 
and 125 µg for 24 hours) and exposures (2 hours, 24 hours, 
or 7 days following 25 µg administration) of microplasmin 
in enzyme-assisted vitrectomy for the treatment of VMA-
related pathologies including tractional DME, VMT, and 
full-thickness macular holes.152 The incidence of spontaneous 
PVD as well as the ease of PVD induction intraoperatively 
were found to be both time- and dose-dependent, although 
no more than 50% of eyes in any one cohort developed 
spontaneous PVD. Of note, the three eyes in the highest dose 
cohort were noted to have vitreoschisis intraoperatively, and 
thus were incorrectly classified as spontaneous PVDs by 
ultrasound. Aside from a single retinal detachment noted 
shortly following microplasmin administration, there were 
no safety concerns ascribed to the study drug. MIVI-IIt (trac-
tion) was a follow-up Phase II prospective sham-controlled 
trial examining the efficacy of microplasmin alone for the 
treatment of VMT and early macular holes.153 In this trial, 
patients were divided into four cohorts and randomized 
4:1 to microplasmin at doses of 75, 125, 175, and repeat-
able 125 µg doses or sham injection and followed with serial 
OCT and ultrasound exams. A significantly higher incidence 
of PVD was noted in the 125 µg cohort as well as the pooled 
(all doses) microplasmin cohort at 90 days, but not at the 
remaining time points (14, 28, and 180 days). At 28 days, 
nonsurgical release of VMA was achieved in 8%, 25%, 
44%, and 27% of patients in the sham, 75, 125, and 175 µg 
cohorts, respectively, with no significant difference observed 
in the overall analysis or in pairwise comparisons. A larger 
multicenter Phase IIb prospective placebo-controlled trial, 
MIVI-III, was subsequently designed to evaluate three doses 
of microplasmin (25, 75, and 125 µg) compared with placebo 
administered 7 days prior to vitrectomy for the treatment of a 
variety of VMA-related disorders.69 No significant pairwise 
differences were found in terms of spontaneous PVD induc-
tion, but there was significantly greater progression of PVD Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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from the date of microplasmin administration until surgery in 
the 125 µg cohort compared with placebo. Within the 125 µg 
cohort, there were also a significantly greater proportion of 
patients in the total cohort as well as within the subset of 
patients with macular holes who achieved resolution of their 
condition without the need for vitrectomy versus placebo. 
Two additional MIVI trials were conducted, but results have 
yet to be formally published. MIVI-II (TG-MV-002) is a 
Phase II sham-controlled non-vitrectomy study in patients 
with tractional DME that completed data collection in March 
2010. MIVI-Trust (Traction Release without Surgical Treat-
ment) (TM-MV-006, TM-MV-007) is a Phase III multicenter, 
randomized, placebo-controlled trial evaluating 125 µg of 
microplasmin alone for the treatment of focal VMA associ-
ated with subjective visual dysfunction, a concept the study 
designers have labeled “symptomatic VMA,” that completed 
data collection in July 2010. The preliminary results of this 
latter trial were reported at the 2011 ARVO (Association 
for Research in Vision and Ophthalmology) meeting and 
indicated a statistically significant improvement in the rate 
of pharmacological resolution of symptomatic VMA in 
the microplasmin group compared with placebo.154 Formal 
publication of results from both of these studies should be 
forthcoming in the near future.
RGD peptides
Widely expressed cell surface receptors, integrins, play 
a critical role in cellular-ECM adhesion and signaling.155 
Binding to integrins is mediated through a specific bind-
ing motif – defined by the amino acid sequence arginine-
glycine-aspartate (RGD) – present in a vast array of ECM 
components including laminin, fibronectin, and certain 
collagens.155 Synthetic RGD peptides are known to com-
pete for integrin binding sites, which results in disruption 
of integrin-ECM interaction and subsequent loosening of 
attachments.156 As immunolocalization studies have identi-
fied integrins on the surface of the ILM,157 there has been 
considerable speculation regarding a possible role of syn-
thetic RGD peptides in disrupting vitreorentinal adhesion, 
and by extension, a potential utility in vitreolysis. In a rab-
bit model, 24-hour incubation of intravitreal RGD peptides 
followed by limited vitrectomy – consisting of 30-second 
core vitrectomy with attempted PVD induction at low 
aspiration (#30 mmHg) – resulted in a significantly greater 
extent of PVD in treated eyes compared with controls; 
however, only a single treated eye achieved complete PVD. 
Aside from focal retinal edema noted in half of the treated 
eyes, no toxicity was detected on clinical examination, EM 
analysis, or TUNEL (terminal deoxynucleotidyl transferase 
dUTP nick end   labeling) apoptosis assay.158 Despite the 
modest success of this initial study, no further studies have 
been published.
vitreosolve®
Vitreosolve® (Vitreoretinal Technologies Inc, Irvine, CA) is 
a proprietary nonenzymatic, urea-based molecule currently 
undergoing Phase II/III testing (PVD-301, PVD-302) in 
patients with non-proliferative diabetic retinopathy without 
pre-existing PVD. Given the proprietary nature of the agent, 
there is little information regarding its structure or mecha-
nism. Preliminary results from an earlier, unpublished study 
demonstrated PVD induction in 45% of patients following 
a single 12 mg injection with the proportion rising to 75% 
following a second injection 30 days later.159 As Phase II/
III trials are currently enrolling patients, final results may 
be pending for some time.
Conclusion
Medical therapy of VMA-related disorders is an exciting 
and promising area of investigation but currently remains 
an incompletely realized technology. To facilitate the 
identification of new agents and maximize the therapeutic 
potential of current vitreolytics, additional efforts are needed 
to expand present knowledge of vitreous molecular struc-
ture and physiology. Future work on existing agents will 
undoubtedly draw on the studies reviewed above, though 
care must be taken in evaluating this body of literature. 
Two characteristics of previous study design warrant further 
discussion: PVD definition and clinical model. The modality 
used to assess for the presence of PVD varies significantly 
between studies – ranging from clinical examination to 
ultrasonography to EM – thus complicating inter-study 
comparison. Moreover, the definition of complete PVD dif-
fered significantly and was often related to the assessment 
modality employed; complete PVD by microscopy typically 
signified the absence of collagen fibrils on the small speci-
men of ILM examined, while OCT and ultrasound looked 
more macroscopically – though perhaps less sensitively – 
at the vitreoretinal interface. The considerable variability 
in choice of clinical models also impacts study outcomes. 
Physiologic PVD is not known to occur in either rabbit61 
or pig eyes124 – indicating a distinctly different vitreous 
physiology – and differences in ILM thickness might exag-
gerate perceived toxicities in certain models.36 Additionally, 
use of cadaver models may be confounded by differences 
in temperature, pH, solubility parameters, and electrolyte Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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concentrations, which vary depending on the duration of   
the post-mortem period.160
Study design issues notwithstanding, many of the agents 
examined to date have shown the capacity to produce signifi-
cant degrees of vitreous liquefaction or weakening of vitreo-
rentinal adhesion. Unfortunately, these changes are rarely 
induced concurrently or in the appropriate proportions to 
induce a safe and reliable PVD. Agents acting either solely 
through liquefaction (liquefactants such as hyaluronidase 
and collagenase) or vitreoretinal interface disruption (inter-
factants such as dispase or RGD peptides) are non-physi-
ologic and have the potential to worsen existing tractional 
pathology. Plasmin-based agents have shown some ability 
to concurrently liquefy vitreous and weaken vitreorentinal 
adhesion; however, the presence of liquefaction is inconsis-
tent and its extent is quite variable.127,131,161 Moreover, some 
investigators suggest that plasmin/microplasmin-associated 
liquefaction is actually due to drug-related inflammation 
and that this change occurs several hours after plasmin 
exerts its effect on the vitreoretinal interface.161 Such tem-
poral separation of the two components of PVD induction 
may ultimately reduce efficacy. This combination of factors 
likely accounts for the surprisingly low rates of spontaneous 
PVD noted in human trials of plasmin and microplasmin, 
which were routinely less than 50%.69,77,134,152,153 As no 
single agent currently appears sufficient for routine PVD 
production, the future of pharmacologic vitreolysis will 
likely involve the simultaneous administration of different 
agents with distinct roles in PVD production.51,90 Two in 
vivo pre-clinical studies, one in rabbits105 and the second in 
diabetic rats,162 have utilized this approach with excellent 
results. In these studies, 80%–100% of eyes treated with a 
combination of hyaluronidase and plasmin/microplasmin 
achieved spontaneous PVD without adjunctive procedure 
compared with much lower rates in eyes treated with the 
individual agents alone (0%–12.5%). Future studies could 
explore the use of different doses and combinations of 
existing agents and could permit the application of agents 
previously found to be associated with significant toxicity 
as combination therapy may allow the use of lower doses. 
Other promising concepts deserving of further exploration 
include the use of nonenzymatic agents, which offer the 
potential for vitreolysis without collateral damage to adja-
cent ECM structures, and the identification of particular 
agents for specific clinical indications.
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